IL10 and ovarian carcinoma: Considering that it has already been demonstrated that PD-1 blockade induced IL-10 secretion by myeloid cells in ovarian cancer [40], these apparent discrepancies could be explained by the fact that six hours of in vitro treatment were not sufficient to allow IL-10 modulation by the anti-PD-1 antibody.